Skip to content

Pancreatic Cancer and Carbon Ion Radiotherapy

Pancreatic Cancer and Carbon Ion Radiotherapy

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04194268
Acronym
PACK
Enrollment
25
Registered
2019-12-11
Start date
2019-12-03
Completion date
2025-11-11
Last updated
2026-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Cancer

Brief summary

Irradiation of non-operable pancreatic cancer with carbon ions (C12). This therapy is expected to be more effective than the current Gold Standard of photon irradiation applied in the case of non-operable pancreatic cancer.

Interventions

RADIATIONCarbon Ion

12 x 4 Gy (RBE)

Sponsors

University Hospital Heidelberg
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed, inoperable primary or local recurrent pancreatic cancer * Written informed consent (must be available before enrollment in the trial) * Karnofsky performance score \> 60 or ECOG-status 0/1 (at least: patient should be able to take care of himself, although daily-life activity or work is not possible) * Age ≥ 18 years

Exclusion criteria

* No clear difference between tumor edge and upper gastrointestinal tract in baseline imaging * Extensive lymphatic metastases * Disability of subject to understand character and individual consequences of the clinical trial * Distant metastases * Previous radiotherapy of the upper abdomen * Active medical implants (e.g. pacemaker, defibrillator), contradicting radiotherapy at HIT * Participation in another clinical study or observation period of competing trials, respectively

Design outcomes

Primary

MeasureTime frameDescription
survival12 month after radiationoverall survival

Secondary

MeasureTime frameDescription
Blood Parameters Ca 19-948 Month after radiationChange in Ca 19-9
Blood Parameters CEA48 Month after radiationChange in CEA levels
survival12 month after radiationProgression free survival
Quality of life EORTC QLQ Pan2648 Month after radiationChange on scoring EORTC QLQ Pan26
toxicity outcomes48 Month after radiatoinIncidence of grade 3/4 NCI-CTC-AE toxicity
Quality of life (QLQ) EORTC QLQ C3048 Month after radiationChange on scoring on EORTC QLQ C30

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026